This cross-sectional study assessed health-related quality of life (HRQOL) in ambulant and nonambulant patients with Duchenne muscular dystrophy, and explored the association between health-related quality of life and clinically assessed motor function. The Pediatric Quality of Life Inventory (PedsQL) Generic Core Scale and PedsQL Neuromuscular module were completed by 34 parent-child dyads. Association between PedsQL scores and overall motor abilities and the transfers and standing posture domain measured by the Motor Function Measure were examined. Child self-reported and parent proxy-reported mean PedsQL scores for children with Duchenne muscular dystrophy were lower than those for healthy children for the physical and psychosocial health-related quality of life. Fifty-six percent of patients reported clinically impaired psychosocial health-related quality of life scores. Several aspects of the generic and disease-specific health-related quality of life in patients with Duchenne muscular dystrophy were positively associated to overall motor function and transfers and standing posture domain. Associations remained stable when adjusted for age and corticosteroid use. The Motor Function Measure is clinically meaningful in the context of a patient’s day-to-day life.
BushbyKFinkelRBirnkrantDJet al.Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9(1):77–93.
2.
MendellJRShillingCLeslieNDet al.Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol. 2012;71(3):304–313.
3.
HoffmanEPBrownRHKunkelLM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51(6):919–928.
4.
AcquadroCBerzonRDuboisDet al.Incorporating the patient’s perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. Value Health. 2003;6(5):522–531.
5.
MendellJRCsimmaCMcDonaldCMet al.Challenges in drug development for muscle disease: a stakeholders’ meeting. Muscle Nerve. 2007;35(1):8–16.
6.
Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. Fed Regist. 2009;74(235):65132–65133.
7.
World Health Organization. World health organization constitution. Basic Documents, 1948.
8.
SolansMPaneSEstradaMDet al.Health-related quality of life measurement in children and adolescents: a systematic review of generic and disease-specific instruments. Value Health. 2008;11(4):742–764.
9.
WeiYSpeechleyKCampbellC. Health-related quality of life in children with Duchenne muscular dystrophy: a review. J Neuromuscul Dis. 2015;2(3):313–324.
10.
DavisSEHynanLSLimbersCAet al.The PedsQL™ in pediatric patients with Duchenne muscular dystrophy: feasibility, reliability, and validity of the pediatric quality of life inventory neuromuscular module and generic core scales. J Clin Neuromuscul Dis. 2010;11(3):97–109.
11.
IannacconeSTHynanLSMortonABuchananRLimbersCAVarniJW. The PedsQL™ in pediatric patients with spinal muscular atrophy: feasibility, reliability, and validity of the Pediatric Quality of Life Inventory™ generic core scales and neuromuscular module. Neuromuscul Dis. 2009;19(12):805–812.
12.
BendixenRMSenesacCLottDJVandenborneK. Participation and quality of life in children with Duchenne muscular dystrophy using the International Classification of Functioning, Disability, and Health. Health Qual Life Outcomes. 2012;10(1):1.
13.
LandfeldtELindgrenPBellCFet al.Health-related quality of life in patients with Duchenne muscular dystrophy: a multinational, cross-sectional study. Dev Med Child Neurol. 2016;58(5):508–515.
14.
McDonaldCMMcDonaldDABagleyAet al.Relationship between clinical outcome measures and parent proxy reports of health-related quality of life in ambulatory children with Duchenne muscular dystrophy. J Child Neurol. 2010;25(9):1130–1144.
15.
UzarkKKingECripeLet al.Health-related quality of life in children and adolescents with Duchenne muscular dystrophy. Pediatrics. 2012;130(6):e1559–e1566.
16.
WeiYSpeechleyKNZouGCampbellC. Factors associated with health-related quality of life in children with Duchenne muscular dystrophy. J Child Neurol. 2016;31(7):879–886.
17.
BaiardiniIMinettiCBonifacinoSet al.Quality of life in Duchenne muscular dystrophy: the subjective impact on children and parents. J Child Neurol. 2011;26(6):707–713.
18.
HenricsonEAbreschRHanJJet al.The 6-minute walk test and person-reported outcomes in boys with Duchenne muscular dystrophy and typically developing controls: longitudinal comparisons and clinically-meaningful changes over one year. PLoS Curr. 2013;5.
19.
KohlerMClarenbachCFBoüniLBrackTRussiEWBlochKE. Quality of life, physical disability, and respiratory impairment in Duchenne muscular dystrophy. Am J Respir Crit Care Med. 2005;172(8):1032–1036.
20.
OpstalSHvJansenMvan AlfenNde GrootIJ. Health-related quality of life and its relation to disease severity in boys with Duchenne muscular dystrophy: satisfied boys, worrying parents—a case-control study. J Child Neurol. 2014;29(11):1486–1495.
21.
SimonVAResendeMBDSimonMAZanoteliEReedUC. Duchenne muscular dystrophy: quality of life among 95 patients evaluated using the Life Satisfaction Index for Adolescents. Arq Neuropsiquiatr. 2011;69(1):19–22.
22.
MessinaSVitaGLSframeliMet al.Health-related quality of life and functional changes in DMD: a 12-month longitudinal cohort study. Neuromuscul Disord. 2016;26(3):189–196.
23.
HafnerPBonatiUErneBet al.Improved muscle function in Duchenne muscular dystrophy through l-arginine and metformin: an investigator-initiated, open-label, single-center, proof-of-concept-study. PLoS One. 2016;11(1):e0147634.
24.
HafnerPBonatiURubinoDet al.Treatment with l-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial. Trials. 2016;17(1):389.
25.
VarniJWLimbersCABurwinkleTM. Impaired health-related quality of life in children and adolescents with chronic conditions: a comparative analysis of 10 disease clusters and 33 disease categories/severities utilizing the PedsQL™ 4.0 Generic Core Scales. Health Qual Life Outcomes. 2007;5(1):43.
26.
BérardCPayanCHodgkinsonIFermanianJ; Group MCS. A motor function measure scale for neuromuscular diseases. Construction and validation study. Neuromuscul Disord. 2005;15(7):463–470.
27.
VarniJWSeidMRodeCA. The PedsQL™: measurement model for the pediatric quality of life inventory. Med Care. 1999;37(2):126–139.
28.
VarniJWBurwinkleTMSeidMSkarrD. The PedsQL™* 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr. 2003;3(6):329–341.
29.
StreinerDNormanG. Health Measurement Scales: A Practical Guide to Their Development and Use. 4th ed. New York, NY: Oxford University Press; 2008.
30.
FleissJLLevinBPaikMC. Statistical Methods for Rates and Proportions. New York, NY: John Wiley & Sons; 2013.
31.
BrayPBundyACRyanMMNorthKNEverettA. Health-related quality of life in boys with Duchenne muscular dystrophy: agreement between parents and their sons. J Child Neurol. 2010;25(10):1188–1194.
32.
ReadJKinaliMMuntoniFWeaverTGarraldaME. Siblings of young people with Duchenne muscular dystrophy—a qualitative study of impact and coping. Eur J Paediatr Neurol. 2011;15(1):21–28.
33.
BuchananDCLaBarberaCJRoelofsROlsonW. Reactions of families to children with Duchenne muscular dystrophy. Gen Hosp Psychiatry. 1979;1(3):262–269.
34.
ThompsonRJJrZemanJLFanurikDSirotkin-RosesM. The role of parent stress and coping and family functioning in parent and child adjustment to Duchenne muscular dystrophy. J Clin Psychol. 1992;48(1):11–19.
CarnevaleFAAlexanderEDavisMRennickJTroiniR. Daily living with distress and enrichment: the moral experience of families with ventilator-assisted children at home. Pediatrics. 2006;117(1):e48–e60.
37.
YılmazOYıldırımSAÖksüzCAtaySTuranE. Mothers’ depression and health-related quality of life in neuromuscular diseases: role of functional independence level of the children. Pediatr Int. 2010;52(4):648–652.
38.
DidsburyMSKimSMedwayMMet al.Socio-economic status and quality of life in children with chronic disease: a systematic review. J Paediatr Child Health. 2016;52(12):1062–1069.
39.
DarkeJBushbyKLe CouteurAMcConachieH. Survey of behaviour problems in children with neuromuscular diseases. Eur J Paediatr Neurol. 2006;10(3):129–134.
40.
HendriksenJGPoyskyJTSchransDGSchoutenEGAldenkampAPVlesJS. Psychosocial adjustment in males with Duchenne muscular dystrophy: psychometric properties and clinical utility of a parent-report questionnaire. J Pediatr Neuropsychol. 2009;34(1):69–78.
41.
SnowWMAndersonJEJakobsonLS. Neuropsychological and neurobehavioral functioning in Duchenne muscular dystrophy: a review. Neurosci Biobehav Rev. 2013;37(5):743–752.
42.
HintonVJNereoNEFeeRJCyrulnikSE. Social behavior problems in boys with Duchenne muscular dystrophy. J Dev Behav Pediatr. 2006;27(6):470–476.
43.
ColvinMKPoyskyJKinnettKet al.Psychosocial management of the patient with Duchenne muscular dystrophy. Pediatrics. 2018;142(suppl 2):S99–S109.
44.
UptonPLawfordJEiserC. Parent–child agreement across child health-related quality of life instruments: a review of the literature. Qual Life Res. 2008;17(6):895.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
